Is Bcl-2 Useful to Select Endocrine Therapy for Breast Cancer?

Qifeng Yang
Qifeng Yang
Affiliations
The Cancer Institute of New Jersey, UMDNJ—Robert Wood Johnson Medical School, New Brunswick, NJ
Search for articles by this author

This paper is only available as a PDF. To read, Please Download here.

To read this article in full you will need to make a payment

One-time access price info

Already a print subscriber? Claim online access

Already an online subscriber? Sign in

References

- Cardoso F
- Paesmans D
- Larsimont V
- et al.
Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer.
Clin Breast Cancer. 2004; 5: 364-369
- Gasparini G
- Barbareschi M
- Doglioni C
- et al.
Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Clin Cancer Res. 1995; 1: 189-198
- PubMed
- Google Scholar
- Yang Q
- Sakurai T
- Yoshimura G
- et al.
Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
Oncol Rep. 2003; 10: 121-125
- PubMed
- Google Scholar
- Diel P
- Smolnikar K
- Michna H
The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells.
Breast Cancer Res Treat. 1999; 58: 87-97
- Salami S
- Karami-Tehrani F
Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines.
Clin Biochem. 2003; 36: 247-253
- Zhang GJ
- Kimijima I
- Onda M
- et al.
Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels.
Clin Cancer Res. 1999; 5: 2971-2977
- PubMed
- Google Scholar

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes